LEADS BioLabs

Focus: LEADS BioLabs is a Nanjing-based biotechnology company specializing in monoclonal and bispecific antibodies for oncology and immunology indications. The company operates as a clinical-stage biotech with a focus on antibody-based therapeutics.

Oncology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About LEADS BioLabs

AI assessmentNot Hiring

No open roles listed right now. Follow LEADS BioLabs to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

18 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LBL-007

Advanced Melanoma

Phase 1

Clinical Trials (1)

NCT04640545A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Phase 1

Help build intelligence for LEADS BioLabs

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline depth with 18 active programs spanning monoclonal and bispecific antibody platforms, offering exposure to cutting-edge immunotherapy modalities.
Focus on high-unmet-need oncology indications including triple-negative breast cancer, melanoma, and multiple myeloma with multiple Phase 1/2 programs advancing.
Early-stage company positioning offers opportunity to shape core infrastructure, culture, and scientific strategy from the ground up.

Watch Out For

Zero active job openings at present and no disclosed funding, employment size, or revenue data raises transparency and hiring capacity concerns.
All programs remain in Phase 1/2 with no Phase 3 programs in clinic—5+ years minimum to potential approval, creating long timeline to value inflection.
China-based operations may limit visa sponsorship availability and expose candidates to geopolitical/regulatory uncertainty in biotech sector.

Generated by Claude from LEADS BioLabs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LBL-047 for Injection

Systemic Lupus Erythematosus

Phase 1

Clinical Trials (1)

NCT07323173A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

Phase 1

LBL-003 Injection

Advanced Malignant Tumor

Phase 1

Clinical Trials (1)

NCT05042908Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies

Phase 1